Physician profile
Allen L Gee
NPI 1083793863
$7,575.30
in general payments reported to CMS, 2019-2025
44 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $222 · 2021: $2,188 · 2022: $2,731 · 2023: $560 · 2024: $679 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Kinetics USA Corporation | $3,300.00 | 2021-2022 | |
| Celgene Corporation | $464.18 | 2021-2025 | Zeposia |
| Biogen, INC. | $404.67 | 2019-2025 | Tysabri, Vumerity |
| Abbvie INC. | $336.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $297.98 | 2019-2025 | |
| Ucb, INC. | $247.84 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Genentech USA, INC. | $191.93 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $175.26 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $164.91 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $151.32 | 2024 | |
| Neurocrine Biosciences, INC. | $146.79 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $144.57 | 2023-2025 | Vyepti |
| Argenx US, INC. | $119.62 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $112.10 | 2019-2022 | |
| C2n Diagnostics, LLC | $100.09 | 2025 | Precivityad2 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.